BioNotebook: Targacept, AcelRx/Grunenthal, Retrophin/Transcept, AmpliPhi
This article was originally published in Scrip
Executive Summary
Targacept sinks on another failure; AcelRx signs EU Zalviso deal; Retrophin drops Transcept bid; and AmpliPhi nets $16.9m in stock sale.